Development of a Second-Generation RARα Selective Antagonist as an Orally Bioavailable, Effective, Safe, and Reversible Male Contraceptive
does not cross the blood-testis barrier and therefore must exert its activity during the initial phases of spermatogenesis.
Authors
- Narsihmulu Cheryala (ORCID: https://orcid.org/0000-0003-1983-8236)
- Taimeng Liang
- Gunda I. Georg (ORCID: https://orcid.org/0000-0002-8900-9460)
- Kristen John (ORCID: https://orcid.org/0000-0002-9981-6100)
- Ehfazul Haque (ORCID: https://orcid.org/0009-0008-7723-9278)
- Xuan Qin (ORCID: https://orcid.org/0000-0003-3728-5911)
- Rui Shi (ORCID: https://orcid.org/0000-0002-9374-0897)
- Henry L. Wong
- Feng Li
Institutions
- University of Minnesota (US)
- Baylor College of Medicine (US)
- Innovative Design Labs (United States) (US)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-05-11
- DOI
- https://doi.org/10.1021/acs.jmedchem.6c00011
- Primary Topic
- Sperm and Testicular Function
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Medicinal Chemistry Division, American Chemical Society
- Eunice Kennedy Shriver National Institute of Child Health and Human Development